ArticleThe Lancet regional health. Southeast Asia2025
Seroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional study.
Article in The Lancet regional health. Southeast Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Shifting epidemiology and disease severity: Rethinking India's hepatitis A strategy in the context of acute liver failure.Journal of family medicine and primary care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
Background: India accounts for one-fifth of the global hepatitis A virus (HAV) infections and half of HAV-related deaths. There is a lack of nationally representative population-based data on the endemicity of HAV to inform vaccination policy. We aimed to estimate the age-specific seroprevalence of HAV infection among individuals aged 6-30 years. Methods: We used serum samples collected during the fourth national COVID-19 serosurvey conducted between 14 June and 6 July 2021 to estimate the seroprevalence of HAV infection. The survey was conducted in 70 randomly selected districts across 20 Indian states and one union territory. We tested the serum samples from individuals aged six to 30 years for IgG antibodies against HAV. We estimated the overall and state-specific seroprevalence, along with 95% CIs, for the age groups of 6-10, 11-15 and 16-30 years. We classified the HAV endemicity in India using WHO classification (high, intermediate, low and very low). Findings: We tested 14,778 serum samples from individuals aged six to 30 years for IgG antibodies against HAV. Of these, 12,236 (90.0%, 95% CI 88.5-91.4) were found to be reactive. The seroprevalence increased with age, from 74.7% (71.1-77.9) among children aged 6-10 years to 85.2% (82.7-87.4) among those aged 11-15 years and 96.9% (96.3-97.5) among individuals aged 16-30 years. India was categorized as having intermediate endemicity for HAV infection as per the WHO classification. Of the 21 states or union territories included in the survey, 18 had intermediate endemicity. Interpretation: Our study findings indicate an intermediate level of endemicity for HAV infection in India. While these findings support consideration of hepatitis-A vaccination, further evidence on disease burden and cost-effectiveness is needed to inform policy decisions. Funding: Gates Foundation & Indian Council of Medical Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.